Search results | diagnostics

Reports

Molecular Diagnostics Partnering Terms and Agreements

The Molecular Diagnostics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals.

Cancer Diagnostics Partnering Terms and Agreements

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer diagnostics partnering contract documents Top cancer diagnostics deals by value   The more »

Co-development Terms and Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter co-development deals.   Understanding the flexibility of a prospective more »

Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics

The Collaborative R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.   Understanding the more »

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.   The report provides a detailed understand and analysis of how and why companies enter licensing deals.   Understanding the flexibility of a more »

Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics

The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies. This new 1st edition, includes: Trends in joint venture deals Joint venture agreement structure Joint venture contract documents Top joint venture deals by value more »

Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics

The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 10th edition, includes: Trends in co-promotion and co-marketing deals Co-promotion and co-marketing agreement structure Co-promotion and co-marketing more »

Companion Diagnostics Partnering Terms and Agreements

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Diagnostics Partnering Terms and Agreements

The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.

Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics

The Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

Insights

Molecular diagnostics partnering: recent life science trends 2009-2014

Molecular diagnostics is the use of molecular biology for medical testing and clinical applications. This discipline determines how genes and proteins interact in a cell. This partnering article reflects on the recent life science trends in the molecular diagnostics technology arena.

Diagnostics partnering: recent life science trends 2009-2014

Diagnostics are subject to numerous partnering deals every year. Here we provide a review of recent life science trends in deal making activity

Companion diagnostics

Companion diagnostics are assays that measure levels of proteins, genes or specific mutations….

Diagnostics

Diagnostics are any kind of medical test performed to aid in the diagnosis or detection of disease.

Companion diagnostics: recent life science industry trends

Companion diagnostics is an increasingly active component of healthcare business and life science deals development suggests industry trends

J&J receives bids for Ortho Clinical Diagnostics unit

Some of the world’s largest private equity firms have made preliminary offers for Johnson & Johnson’s Ortho Clinical Diagnostics unit

Dealtalk: Johnson & Johnson kicks off $5 billion clinical diagnostics unit sale

In dealtalk, Johnson & Johnson launched a sale process for its Ortho Clinical Diagnostics unit for around $5 billion.

Recent merger and acquisition activity in pharma, biotech and diagnostics

This year has seen a lower frequency in pharma merger and acquisition (M&A) activity with 255 deals announced in the first six months of 2012 compared to 199 deals this year (2013) according to Current Agreements

Biotech rumor mill: J&J selling Ortho Clinical Diagnostics unit?

A biotech rumor mill reports Johnson & Johnson’s plan to sell its Ortho Clinical Diagnostics business if it can find the right price

Bio news: Diagnostics creating ‘niche buster’ drugs

When US regulators this month authorised a genetic test that determines  whether or not patients will benefit from a cancer drug, they heralded an  important acceleration in “personalised medicine” that could turn the  pharmaceutical industry’s business model on its head

Events

Collaborative R&D for prostate cancer prognostic test

Definiens and Metamark Genetics announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark.

Deals

Ventana and Astellas in automated tissue diagnostics pact

Ventana Medical Systems has entered into master collaboration agreement with Astellas Pharma to develop novel automated tissue diagnostics

Roche acquires Signature Diagnostics for access to translational oncology and genomics

Roche announced the acquisition of Signature Diagnostics

Acquisition agreement for Boston Heart Diagnostics

Eurofins Scientific has signed a definitive agreement to acquire Boston Heart Diagnostics Corporation for an initial value of $140 million, subject to post-closing adjustments, plus an earn-out payment to the sellers that is expected to be in excess of $60 million upon achievement of certain milestones.

Quotient BioDiagnostics pulls in $27 million financing

Quotient has entered into agreements to issue to certain subscribers 2,000,000 ordinary shares at $9.50 per share and 850,000 pre-funded warrants at $9.49 per warrant, exercisable for up to 850,000 ordinary shares at $0.01 per ordinary share

Qiagen and Astellas form a biotech partnership to develop companion diagnostics

QIAGEN announced a biotech partnership agreement with Astellas Pharma to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.

MGC Diagnostics to acquire Medisoft.

MGC Diagnostics has completed a stock purchase agreement to acquire Medisoft.

Integrated Diagnostics raises $47 million in equity financing

Integrated Diagnostics has raised $47 million in equity and debt financing.

Exosome Diagnostics gets $27 million in Series B financing

Exosome Diagnostics announced the initial close of its Series B financing round with the raising of $27 million.

Ventana and Bayer ink pharma alliance for development of companion diagnostics

Ventana Medical Systems has entered into a multi-year pharma alliance with Bayer Pharma to develop companion diagnostics, with a focus on immunohistochemistry (IHC), across Bayer’s portfolio of targeted therapy projects.

Quest Diagnostics has entered into a m&a for Solstas

Quest Diagnostics has entered into m&a deal for Solstas Lab Partners  for $570 million.

cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
e79banner300x150gif
e78banner300x150animgif